The intranasal GHK-Cu treatment was found to delay cognitive impairment, reduce amyloid plaques, and lower inflammation levels in the frontal cortex and hippocampus .37 Randomized controlled trials in human patients are needed to confirm the benefit of GHK-Cu for cognitive decline and Alzheimers disease as well as to evaluate safe and effective human dosing (the human dose equivalent of 15mg/kg in mice would be ~1.2mg/kg, though data on this or any other dosing nasally in humans is not currently available), but preliminary animal trials are promising
Available alternatives: Is there already an FDA-approved drug that makes compounding unnecessary
The expiry date refers to the product correctly stored in an unopened package
Plant Physiol 153:11441160 Miller G, Suzuki N, Ciftci-Yilmaz S, Mittler R (2010) Reactive oxygen species homeostasis and signalling during drought and salinity stresses
Heart failure due to stress cardiomyopathy: a severe manifestation of the opioid withdrawal syndrome
Thats itquick, straightforward, and you can easily fit it into a busy schedule